Visceral obesity augments prescription use: An analysis of the cross-sectional study of NHANES 2011–2018

Maximino Acevedo-Fernández, Renata Ochoa Precoma, Leonardo M Porchia, Victor M Posadas, Enrique Torres-Rasgado, M Elba Gonzalez-Mejia and Esther López-Bayghen

PLOS ONE, 2025, vol. 20, issue 2, 1-22

Abstract: Background: Visceral obesity (VATob) increases the risk for many diseases. Central obesity has been associated with an augmented prescription use; however, there is a paucity of research focused on VATob. Here, the aim was to evaluate the association between VATob and prescription use. Methods: Data was collected from the NHANES dataset (2011–2018). Visceral adipose tissue was measured using dual x-ray absorptiometry, and VATob was defined as ≥100 cm2. Prescription use was collected from the RXQ_RX files and classified according to Vademecum. Association between VATob and prescription use was determined with logistic regression and reported as odds ratios (ORs) with 95% confidence intervals (95%CIs). Results: 10,952 participants (weighted: 121,090,702) were included, in which 41.8% were VATob and 52.0% of them had ≥1 prescription. Overall, VATob demonstrated an augmented rate of prescription use when compared to non-VATob (52.0% versus 36.7%, p

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0318413 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 18413&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0318413

DOI: 10.1371/journal.pone.0318413

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().